93 related articles for article (PubMed ID: 28645266)
1. Poorer outcomes among cancer patients diagnosed with Clostridium difficile infections in United States community hospitals.
Delgado A; Reveles IA; Cabello FT; Reveles KR
BMC Infect Dis; 2017 Jun; 17(1):448. PubMed ID: 28645266
[TBL] [Abstract][Full Text] [Related]
2. Do admissions and discharges to long-term care facilities influence hospital burden of Clostridium difficile infection?
Ricciardi R; Nelson J; Griffith JL; Concannon TW
J Hosp Infect; 2012 Feb; 80(2):156-61. PubMed ID: 22137065
[TBL] [Abstract][Full Text] [Related]
3. Excess length of hospital stay, mortality and cost attributable to
Kimura T; Stanhope S; Sugitani T
Epidemiol Infect; 2020 Mar; 148():e65. PubMed ID: 32115019
[TBL] [Abstract][Full Text] [Related]
4. Multicenter study of surveillance for hospital-onset Clostridium difficile infection by the use of ICD-9-CM diagnosis codes.
Dubberke ER; Butler AM; Yokoe DS; Mayer J; Hota B; Mangino JE; Khan YM; Popovich KJ; Stevenson KB; McDonald LC; Olsen MA; Fraser VJ;
Infect Control Hosp Epidemiol; 2010 Mar; 31(3):262-8. PubMed ID: 20100085
[TBL] [Abstract][Full Text] [Related]
5. Impact of the NAP-1 strain on disease severity, mortality, and recurrence of healthcare-associated Clostridium difficile infection.
Bauer KA; Johnston JEW; Wenzler E; Goff DA; Cook CH; Balada-Llasat JM; Pancholi P; Mangino JE
Anaerobe; 2017 Dec; 48():1-6. PubMed ID: 28645479
[TBL] [Abstract][Full Text] [Related]
6. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.
Tian JH; Glenn G; Flyer D; Zhou B; Liu Y; Sullivan E; Wu H; Cummings JF; Elllingsworth L; Smith G
Vaccine; 2017 Jul; 35(33):4079-4087. PubMed ID: 28669616
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of Clostridium perfringens toxin in patients suspected of having antibiotic-associated diarrhea.
Kim YJ; Kim SH; Ahn J; Cho S; Kim D; Kim K; Lee H; Son H; Lee HJ; Yong D; Choi JY; Kim HR; Shin JH
Anaerobe; 2017 Dec; 48():34-36. PubMed ID: 28655582
[TBL] [Abstract][Full Text] [Related]
8. Clinical and molecular characteristics of community-acquired Clostridium difficile infections in comparison with those of hospital-acquired C. difficile.
Kwon SS; Gim JL; Kim MS; Kim H; Choi JY; Yong D; Lee K
Anaerobe; 2017 Dec; 48():42-46. PubMed ID: 28655581
[TBL] [Abstract][Full Text] [Related]
9. Vancomycin vs Metronidazole for Clostridium difficile infection: focus on recurrence and mortality.
Wu MA; Leidi F;
Intern Emerg Med; 2017 Sep; 12(6):871-872. PubMed ID: 28681270
[No Abstract] [Full Text] [Related]
10. Is Clostridium difficile infection a risk factor for subsequent bloodstream infection?
Ulrich RJ; Santhosh K; Mogle JA; Young VB; Rao K
Anaerobe; 2017 Dec; 48():27-33. PubMed ID: 28669864
[TBL] [Abstract][Full Text] [Related]
11. Reducing Fluoroquinolone Use Is a Key Step in Controlling the Burden of Clostridium difficile Infection.
Walker T; Ciorba M; Dubberke ER
Gastroenterology; 2017 Aug; 153(2):606-607. PubMed ID: 28668696
[No Abstract] [Full Text] [Related]
12. Impact of end stage kidney disease on costs and outcomes of Clostridium difficile infection.
Goyal A; Chatterjee K; Yadlapati S; Rangaswami J
Int J Infect Dis; 2017 Sep; 62():8-9. PubMed ID: 28645569
[TBL] [Abstract][Full Text] [Related]
13. Clostridioides difficile recurrence in individuals with and without cancer: a Swedish population-based cohort study.
Mpakaniye P; Boven A; Callens S; Engstrand L; Vlieghe E; Brusselaers N
Infection; 2024 Apr; 52(2):649-660. PubMed ID: 38407777
[TBL] [Abstract][Full Text] [Related]
14. Leveraging diverse cell-death patterns to predict the clinical outcome of immune checkpoint therapy in lung adenocarcinoma: Based on muti-omics analysis and vitro assay.
Liang H; Li Y; Qu Y; Zhang L
Oncol Res; 2023; 32(2):393-407. PubMed ID: 38186574
[TBL] [Abstract][Full Text] [Related]
15. Increased Prevalence of Clostridioides difficile Infection Among Pediatric Oncology Patients: Risk Factors for Infection and Complications.
Murphy BR; Dailey Garnes NJ; Hwang H; Peterson CB; Garey KW; Okhuysen P
Pediatr Infect Dis J; 2024 Feb; 43(2):136-141. PubMed ID: 38134390
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of antimicrobial resistance in cancer patients: a systematic review of multivariable models.
Danielsen AS; Franconeri L; Page S; Myhre AE; Tornes RA; Kacelnik O; Bjørnholt JV
BMC Infect Dis; 2023 Apr; 23(1):247. PubMed ID: 37072711
[TBL] [Abstract][Full Text] [Related]
17. A case-control study of Clostridioides difficile symptomatic infections in a pediatric cancer hospital.
Silva AMPSD; Barbosa LC; Marques LMA; Carreira LY; Fonseca FMCD; Lima APC; Sodré JJM; Pignati LT; Araújo OR; Silva DCBD; Carlesse FAMC
Rev Paul Pediatr; 2023; 41():e2022117. PubMed ID: 36921180
[TBL] [Abstract][Full Text] [Related]
18. Performance of Clostridioides difficile infection severity scores and risk factors related to 30-day all-cause mortality in patients with cancer.
De-la-Rosa-Martinez D; Zinser-Peniche P; Martin-Onraet A; Rivera-Buendía F; Vilar-Compte D
Support Care Cancer; 2023 Feb; 31(3):187. PubMed ID: 36843052
[TBL] [Abstract][Full Text] [Related]
19. Clinical Impact of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Associated
Chung YS; Lin YC; Hung MS; Ho MC; Fang YH
Onco Targets Ther; 2022; 15():1563-1571. PubMed ID: 36597497
[TBL] [Abstract][Full Text] [Related]
20. The Role of Bezlotoxumab for the Prevention of Recurrent
Hyte ML; Arphai LJ; Vaughn CJ; Durham SH
Antibiotics (Basel); 2022 Sep; 11(9):. PubMed ID: 36139989
[No Abstract] [Full Text] [Related]
[Next] [New Search]
